Malignant Mesothelioma - Pipeline Review, H2 2015

Date: December 16, 2015
Pages: 372
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M07150376F6EN
Leaflet:

Download PDF Leaflet

Malignant Mesothelioma - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Malignant Mesothelioma - Pipeline Review, H2 2015’, provides an overview of the Malignant Mesothelioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Malignant Mesothelioma Overview
Therapeutics Development
Pipeline Products for Malignant Mesothelioma - Overview
Pipeline Products for Malignant Mesothelioma - Comparative Analysis
Malignant Mesothelioma - Therapeutics under Development by Companies
Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes
Malignant Mesothelioma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Malignant Mesothelioma - Products under Development by Companies
Malignant Mesothelioma - Products under Investigation by Universities/Institutes
Malignant Mesothelioma - Companies Involved in Therapeutics Development
Aduro BioTech, Inc.
Advantagene, Inc.
Aeolus Pharmaceuticals, Inc.
Amphera BV
AnGes MG, Inc.
arGEN-X BV
ArQule, Inc.
AVEO Pharmaceuticals, Inc.
Bayer AG
Berg LLC
Biogen, Inc.
Bionomics Limited
Biotecnol, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
CanBas Co., Ltd.
Concordia Healthcare Corp.
CritiTech, Inc.
Deciphera Pharmaceuticals, LLC
Eagle Pharmaceuticals, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genelux Corporation
GlaxoSmithKline Plc
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Oxford BioMedica Plc
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Progenra, Inc.
Sellas Inc.
Sorrento Therapeutics, Inc.
Synta Pharmaceuticals Corp.
Targovax AS
TRACON Pharmaceuticals, Inc.
VasGene Therapeutics, Inc.
Verastem, Inc.
Virttu Biologics Limited
Y's Therapeutics Co., Ltd.
Malignant Mesothelioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ad5-SGE-REIC/Dkk3 - Drug Profile
AEOL-10150 - Drug Profile
alisertib - Drug Profile
amatuximab - Drug Profile
anetumab ravtansine - Drug Profile
ARGX-110 - Drug Profile
ascrinvacumab - Drug Profile
AV-203 - Drug Profile
avelumab - Drug Profile
bevacizumab - Drug Profile
BG-00001 - Drug Profile
BIW-8962 - Drug Profile
BMS-986148 - Drug Profile
BNC-105 - Drug Profile
CB-839 - Drug Profile
CBP-501 - Drug Profile
Cellular Immunotherapy 2 for Oncology - Drug Profile
Cellular Immunotherapy for Cancer - Drug Profile
Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile
Cellular Immunotherapy to Target CSPG4 for Oncology - Drug Profile
CRS-207 - Drug Profile
Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile
DP-3975 - Drug Profile
DPV-001 - Drug Profile
E-7449 - Drug Profile
FL-118 - Drug Profile
FP-1039 - Drug Profile
ganetespib - Drug Profile
GEN-0101 - Drug Profile
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile
GLONC-1 - Drug Profile
GSK-2256098 - Drug Profile
HSV-1716 - Drug Profile
iCasp9M28z - Drug Profile
JTCR-016 - Drug Profile
KPT-251 - Drug Profile
LY-3023414 - Drug Profile
MesoCancerVac - Drug Profile
MesoCART - Drug Profile
Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile
MV-NIS - Drug Profile
napabucasin - Drug Profile
NGR-hTNF - Drug Profile
nintedanib - Drug Profile
nivolumab - Drug Profile
ONCOS-102 - Drug Profile
Oshadi D + Oshadi R - Drug Profile
OXB-301 - Drug Profile
P-0005091 - Drug Profile
paclitaxel - Drug Profile
pegargiminase - Drug Profile
pembrolizumab - Drug Profile
pemetrexed disodium - Drug Profile
porfimer sodium - Drug Profile
rAd-IFN - Drug Profile
Small Molecules to Inhibit Bcl-2 Survival Proteins for Cancer - Drug Profile
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile
TargomiRs - Drug Profile
Tb-535 - Drug Profile
tivantinib - Drug Profile
trabectedin - Drug Profile
TRC-102 - Drug Profile
tremelimumab - Drug Profile
ubidecarenone - Drug Profile
Vaccine for Cancer - Drug Profile
Vaccine to Target WT1 for Cancer - Drug Profile
Vas-01 - Drug Profile
VS-4718 - Drug Profile
VS-5584 - Drug Profile
YS-110 - Drug Profile
Malignant Mesothelioma - Recent Pipeline Updates
Malignant Mesothelioma - Dormant Projects
Malignant Mesothelioma - Discontinued Products
Malignant Mesothelioma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Malignant Mesothelioma, H2 2015
Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd.1)
Number of Products under Development by Companies, H2 2015 (Contd.2)
Number of Products under Development by Companies, H2 2015 (Contd.3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Development by Companies, H2 2015 (Contd.3)
Products under Investigation by Universities/Institutes, H2 2015
Malignant Mesothelioma - Pipeline by Aduro BioTech, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Advantagene, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Amphera BV, H2 2015
Malignant Mesothelioma - Pipeline by AnGes MG, Inc., H2 2015
Malignant Mesothelioma - Pipeline by arGEN-X BV, H2 2015
Malignant Mesothelioma - Pipeline by ArQule, Inc., H2 2015
Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Bayer AG, H2 2015
Malignant Mesothelioma - Pipeline by Berg LLC, H2 2015
Malignant Mesothelioma - Pipeline by Biogen, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Bionomics Limited, H2 2015
Malignant Mesothelioma - Pipeline by Biotecnol, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Malignant Mesothelioma - Pipeline by Boston Biomedical, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Malignant Mesothelioma - Pipeline by Calithera Biosciences, Inc., H2 2015
Malignant Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2015
Malignant Mesothelioma - Pipeline by Concordia Healthcare Corp., H2 2015
Malignant Mesothelioma - Pipeline by CritiTech, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Eisai Co., Ltd., H2 2015
Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H2 2015
Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2015
Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Malignant Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Genelux Corporation, H2 2015
Malignant Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2015
Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc., H2 2015
Malignant Mesothelioma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Malignant Mesothelioma - Pipeline by MedImmune, LLC, H2 2015
Malignant Mesothelioma - Pipeline by Merck & Co., Inc., H2 2015
Malignant Mesothelioma - Pipeline by Merck KGaA, H2 2015
Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Malignant Mesothelioma - Pipeline by MolMed S.p.A., H2 2015
Malignant Mesothelioma - Pipeline by Morphotek, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Novartis AG, H2 2015
Malignant Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Malignant Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2015
Malignant Mesothelioma - Pipeline by Pfizer Inc., H2 2015
Malignant Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2015
Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Progenra, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Sellas Inc., H2 2015
Malignant Mesothelioma - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Malignant Mesothelioma - Pipeline by Targovax AS, H2 2015
Malignant Mesothelioma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
Malignant Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Verastem, Inc., H2 2015
Malignant Mesothelioma - Pipeline by Virttu Biologics Limited, H2 2015
Malignant Mesothelioma - Pipeline by Y's Therapeutics Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Malignant Mesothelioma Therapeutics - Recent Pipeline Updates, H2 2015
Malignant Mesothelioma - Dormant Projects, H2 2015
Malignant Mesothelioma - Dormant Projects (Contd.1), H2 2015
Malignant Mesothelioma - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Malignant Mesothelioma, H2 2015
Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Aduro BioTech, Inc.
Advantagene, Inc.
Aeolus Pharmaceuticals, Inc.
Amphera BV
AnGes MG, Inc.
arGEN-X BV
ArQule, Inc.
AVEO Pharmaceuticals, Inc.
Bayer AG
Berg LLC
Biogen, Inc.
Bionomics Limited
Biotecnol, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
CanBas Co., Ltd.
Concordia Healthcare Corp.
CritiTech, Inc.
Deciphera Pharmaceuticals, LLC
Eagle Pharmaceuticals, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genelux Corporation
GlaxoSmithKline Plc
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Oxford BioMedica Plc
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Progenra, Inc.
Sellas Inc.
Sorrento Therapeutics, Inc.
Synta Pharmaceuticals Corp.
Targovax AS
TRACON Pharmaceuticals, Inc.
VasGene Therapeutics, Inc.
Verastem, Inc.
Virttu Biologics Limited
Y's Therapeutics Co., Ltd.
Skip to top


Malignant Pleural Mesothelioma - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 315 pages
Recurrent Malignant Glioma - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 61 pages
Recurrent Malignant Glioma - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 59 pages
Malignant Glioma - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 116 pages
Malignant Mesothelioma - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Malignant Mesothelioma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: